; (B) geneticists with expertise in pediatric cardiomyopathy and heart failure; (C) cardiovascular molecular biologists; (D) pharmacologists; (E) research scientists with expertise in cardiomyopathy and heart failure; and (F) other stakeholders with relevant expertise, as determined by the Secretary. (4) Report to Congress Not later than 2 years after the date of the enactment of this Act, the Working Group shall publish and submit to Congress a report that contains— (A) a description of the activities of the working group; (B) the findings and recommendations of the working group with respect to each of the topics described in paragraph (2); and (C) the recommendations of the working group relating to actions that Federal agencies and Congress can take to implement the recommendations described in subparagraph (B). (5) No compensation A member of the working group shall serve without compensation. (6) Termination The working group shall terminate on the date on which the working group submits the report under paragraph (4). (7) Cardiomyopathy defined For purposes of this subsection, the term cardiomyopathy means a heart disease that affects the heart’s muscle (myocardium)— (A) the symptoms of which may vary from case to case, including— (i) cases in which no symptoms are present (asymptomatic); and (ii) cases in which there are symptoms of a progressive condition that may result from an impaired ability of the heart to pump blood, such as fatigue, irregular heartbeats (arrhythmia), heart failure, and, potentially, sudden cardiac death; and (B) the recognized types of which include dilated, hypertrophic, restrictive, ar­rhyth­mo­gen­ic right ventricular dysplasia, and left ventricular non-compaction.